Alltrna recently announced the initiation of the first clinical trial of a tRNA therapeutic, AP003. AP003 is designed to restore full-length protein production by inserting the correct amino acid at an ARG-TGA premature termination or stop codon. This is also called a nonsense variant, which can occur across many different rare genetic conditions, including in some people with organic acidemias.

The Phase 1 study is designed to evaluate the safety and pharmacokinetics of single ascending doses of AP003 in healthy volunteers. Data from this study are expected to inform subsequent clinical development, including studies in genetically defined patient populations.

This is one reason genetic variant testing can be so important, because understanding the exact variant may help clarify whether emerging mutation-defined research or future clinical studies could be relevant.

Learn more about genetic testing and the value of understanding the specific variants: https://oaanews.org/our-resources/genetic-testing/

For an explainer on tRNA and Stop Codon Disease, visit: https://lnkd.in/dbdTXqeB